Lys-MDMA, or lysine-MDMA, also known as N-(L-lysinamidyl)-MDMA, is an intended prodrug of MDMA which was being investigated for possible use as a pharmaceutical drug in the treatment of psychiatric disorders. Structurally, lys-MDMA is the amide formed through condensation of MDMA's amine group with the carboxylic acid of lysine; in this way, lys-MDMA is to MDMA as lisdexamfetamine is to dextroamphetamine. As of August 2024, a phase 1 clinical trial comparing MDMA, MDA, lys-MDMA, and lys-MDA has been conducted and completed. Lys-MDMA was being developed by MindMed. The published phase 1 clinical trial unexpectedly found that lys-MDMA does not convert into MDMA in humans and is completely inactive. This is in contrast to lisdexamfetamine and lys-MDA, which are converted into dextroamphetamine and MDA, respectively. The lack of conversion was attributed to steric hindrance caused by the N-methyl group of lys-MDMA.
See also Substituted methylenedioxyphenethylamine List of investigational hallucinogens and entactogens Lys-MDA Lisdexamfetamine Lomardexamfetamine DA-Phen Phenatine MiHKAL
References
External links Lysine-MDMA - Isomer Design